CTX-M: changing the face of ESBLs in the UK
Authors:
Open Access
- 8 July 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 56 (3) , 451-454
Abstract
The UK has experienced a sudden rise in extended-spectrum β-lactamase (ESBL) rates, largely due to the appearance and spread of Escherichia coli producing CTX-M-15 type β-lactamase. The British Society for Antimicrobial Chemotherapy organized two update meetings during 2004 to report and discuss the recognition, clinical diagnosis, treatment and control of bacteria producing these β-lactamases. This paper reports the data and reviews made by contributors to the conferences. The historical distribution and emergence of ESBLs was reviewed along with the emergence of plasmid-mediated CTX-M ESBLs following their mobilization from the chromosome of Kluyvera spp. The first significant outbreak of CTX-M producers in the UK occurred in 2001 and involved Klebsiella pneumoniae with CTX-M-26 at one site, but by 2003, cloned and diverse E. coli with CTX-M-15 were widespread, with Shropshire one of the most affected regions. The specific experience in Shropshire was reported on and a comprehensive review made of the level of awareness of the need for ESBL detection in laboratories in England and Wales, together with a description of the variety of methods that may be applied, with recommendations for optimal methodology. The increased mortality associated with inappropriate treatment of infections caused by ESBL-producing strains was highlighted, together with discussion on potential control of cross-infection. The meeting concluded that the CTX-M genes have now become widespread in not only E. coli but other Enterobacteriaceae in the UK and this will represent a substantial threat to both the treatment of infections caused by these bacteria in the community and within hospitals.Keywords
This publication has 31 references indexed in Scilit:
- Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UKJournal of Antimicrobial Chemotherapy, 2004
- Dissemination of CTX-M type β-lactamases in Enterobacteriaceae isolates in the People’s Republic of ChinaInternational Journal of Antimicrobial Agents, 2004
- Growing Group of Extended-Spectrum β-Lactamases: the CTX-M EnzymesAntimicrobial Agents and Chemotherapy, 2004
- Prevalence of Clinical Isolates of Escherichia coli Producing Inhibitor-Resistant β-Lactamases at a University Hospital in Barcelona, Spain, over a 3-Year PeriodAntimicrobial Agents and Chemotherapy, 2002
- Early Dissemination of CTX-M-Derived Enzymes in South AmericaAntimicrobial Agents and Chemotherapy, 2002
- Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance ThreatClinical Microbiology Reviews, 2001
- Prevalence and mechanism of resistance to 'third-generation' cephalosporins in clinically relevant isolates of Enterobacteriaceae from 43 hospitals in the UK, 1990-1991Journal of Antimicrobial Chemotherapy, 1997
- Characterization of a novel extended-spectrum beta-lactamase from Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 1993
- Extended-spectrum beta-lactamasesAntimicrobial Agents and Chemotherapy, 1989
- Evolution of plasmid-coded resistance to broad-spectrum cephalosporinsAntimicrobial Agents and Chemotherapy, 1985